- Head of Biotech Private Investments
- Boston
Skip to main content
- Funds
- Insights
- Capabilities
- About Us
- My Account
At a glance
San Diego, CA
City, State
2020
Year founded
25 August 2022
Investment date
Irina Margine
Deal lead
Biotech
Sector
Series D Preferred
Series invested
Company overview
Rayzebio is a biotechnology company focused on developing targeted radiopharmaceutical drugs for solid tumors in cancers. The team prosecutes diverse sets of binders against clinically validated cancer targets through an iterative process involving in-vitro screening, X-ray crystallography, linker and radiolabeling optimization, and in-vivo screening with molecular imaging and biodistribution analysis.
Investment thesis
Our August 2022 investment in RayzeBio was centered on the strength of the clinical data for their lead asset (RZE-101). We believe the drug targets a well-defined market with remaining unmet need and that the company has emerged as one of the leaders in the space with their experienced team, strategy execution, manufacturing capabilities, and strong support from a high-quality shareholder base.
Given Wellington's long track record within the healthcare space, and success working with innovative biotech companies, it's a no-brainer for any entrepreneur to want to have Wellington as an investor.
The statement and opinion presented above is an endorsement provided by Dr. Ken Song, CEO of Rayzebio, a portfolio company in which a Wellington-advised client invests. He is not an investor in private funds managed by Wellington Management. Wellington Management has not provided any cash or non-cash compensation for the use of this statement. The ownership structure of portfolio company investments creates a conflict of interest since Senior Executives have an incentive to make positive statements about Wellington and their experiences to maintain goodwill. This statement describes Song’s experience with Wellington Management and/or its supervised persons and may not be representative of the experience of others.
We believe RayzeBio’s strong clinical data, experienced team, and robust manufacturing capabilities make them a leader in the radiopharmaceutical space addressing critical unmet needs for cancer patients.
Meet the private biotech team